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Abstract
Background: Many congenitally cytomegalovirus-infected (cCMV) neonates are at risk for severe consequences,
even if they are asymptomatic at birth. The assessment of the viral load in neonatal blood could help in identifying
the babies at risk of sequelae.
Methods: In the present study, we elaborated the results obtained on blood samples collected in the first two
weeks of life from 22 symptomatic and 48 asymptomatic newborns with cCMV diagnosed through urine testing.
We evaluated the performances of two quantitative methods (pp65 antigenemia test and plasma Real-time PCR)
and the semi-quantitative results of dried blood sample (DBS) test in the aim of identifying a valid method for
measuring viral load.
Results: Plasma qPCR and DBS tests were positive in 100% of cases, antigenemia in 81%. Only the latter test gave
quantitatively different results in symptomatic versus asymptomatic children. qPCR values of 103 copies/ml were
found in 52% of newborn. “Strong” DBS test positivity cases had higher median values of both pp65 positive PBL
and DNA copies/ml than cases with a “weak” positivity.
Conclusions: As expected antigenemia test was less sensitive than molecular tests and DBS test performed better
on samples with higher rates of pp65 positive PBL and higher numbers of DNA copies/ml. The prognostic
significance of the results of these tests will be evaluated on completion of the ongoing collection of follow-up
data of these children.
Background
Congenital cytomegalovirus infection (cCMV) is present
in 0.7% of neonates [1] and represents one of the most
feared events during pregnancy, causing not only
immediate but also delayed sequelae to the infant. At
birth, 10% of infected newborns present with symptoms
involving the hematopoietic, hepatobiliary, or central
nervous systems.
During early childhood, one fifth of all congenitally
infected babies either die or suffer permanent neurologi-
cal impairments that can affect normal development,
particularly psychomotor retardation, ocular damage, or
sensorineural hearing loss (SNHL). This last sequelae is
the most frequent, occurring in about 20% of cases. It
may be evident at birth (45-65%) [1] or develop later.
Moreover, there may be different degrees of severity and
it may be progressive.
As corrective measures may only be successful if car-
ried out immediately, having diagnostic tools available
to promptly identify an infected child is essential. This
is most useful for children with late-onset SNHL, since
the median age for detection of hearing loss is of 27
months (range, 25-62 months) [2].
It is also important to use virological markers that
indicate an unfavorable prognosis to identify newborns
at risk of developing serious problems. This forms the
basis for organizing close follow-up, early rehabilitation,
and/or therapy to minimize long-term damage.
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The viral load in biological samples, such as urine and
peripheral blood leukocytes (PBL) during the neonatal
period was proposed by some investigators as a prog-
nostic marker of developing hearing loss [3-6].
In this study we evaluated the quantitative results of
two blood assays (pp65 antigenemia test and Real-time
PCR) and the semi-quantitative results of dried blood
sample (DBS) test, obtained in our routine diagnostic
activity, in the aim of identifying a valid method for
measuring viral load. On completion of the ongoing col-
lection of follow-up data of the studied children, it will
be possible to assess its prognostic significance.
Methods
Cases
In this study we retrieved and elaborated the results of
tests previously performed in our laboratory on blood
samples as part of the protocol for cCMV diagnosis.
Samples had been collected from 70 consecutive new-
borns (32 females and 38 males) whose cCMV infection
had been diagnosed on the basis of a positive rapid iso-
lation test (SV assay) from urine specimens collected in
the first two weeks of life.
Twenty-two newborns (31%) showed symptoms of
congenital infection at birth [7]. The other 48 newborns
were asymptomatic: 44 of these had been examined hav-
ing been delivered from mothers with a confirmed pri-
mary infection during pregnancy and 2 were identified
during a study of newborns from HIV+ mothers, while
evidence of exposure to risk factors was not indicated
for the 2 remaining newborns.
No data of follow-up are available yet.
Since this was a retrospective and methodological study
on the results already available with us, it was not put up
for any clearance to an ethical committee. All the patient
files are confidential and none could be identified.
Methods
Antigenemia test (pp65)
The leukocyte fraction (PBL) was separated from each
blood sample for antigenemia testing in IF assay (CINA
pool pp65, Argene). The result was expressed as the
number of positive cells in 2 × 105 PBL [8].
Real-time Quantitative PCR (qPCR)
CMV-DNA was extracted from 200 μl of separated
plasma using the QIAamp DNA Mini kit (QIAGEN)
according to the manufacturer’s protocol. The amount
of viral DNA extracted was then measured in a com-
mercial quantitative PCR assay (Q-CMV Real Time
Complete Kit, Nanogen) following the supplier’s instruc-
tions. The results were expressed as copies/ml.
DBS test
Viral DNA in dried blood samples (DBS test) from new-
borns was tested as described by Binda et al. [9]. CMV
DNA was eluted from 3-mm diameter disks, extracted
by means of thermal shock and used as the template for
a nested PCR specific for a highly conserved region of
the CMV gB gene (nt 1942 - nt 2067) [10]. The result
was interpreted following an algorithm described by
Barbi et al. [11], requiring that the test be done on
three series of punches.
The positive results were distinguished as:
- “strong” if at least two out of three tests were
positive
- “weak” if one out of three tests was confirmed posi-
tive in a further series of three.
Statistical analysis
The association between DBS test results (weak or
strong) and the presence of symptoms was tested using
Fisher’s exact test, while the Mann-Whitney U test was
performed to compare symptomatic and asymptomatic
newborn’s median number of positive cells in the pp65
antigenemia test, and the median number of CMV DNA
copies detected by qPCR. A p-value of 0.05 was consid-
ered significant.
Results and discussion
Results from the blood samples of all 70 neonates were
obtained with the DBS test, whilst the presence of inhi-
bitors hampered the assessment of the number of DNA
copies by qPCR in the plasma of three children, and the
low PBL counts precluded the determination of the
pp65 antigenemia in two cases.
The pp65 antigenemia test was positive in 81% (55/68)
of samples tested. Compared with children who had
asymptomatic infections, those with symptoms had a
Table 1 Results of the pp65 (antigenemia), qPCR, and DBS tests in symptomatic and asymptomatic newborns
pp65 (no. cells pos/2 × 105PBL) qPCR (no. copies/ml) DBS test
Positive (%) Median IQR° Positive (%) Median IQR° Positive (%) Weak Strong
Symptomatic 19/21 (90.5%) 8.0 2-33 22/22 (100.0%) 8,701 1,777-39,945 22/22 (100.0%) 3 19
Asymptomatic 36/47 (76.6%) 3.0 2-7 45/45 (100.0%) 5,383 2,359-11,896 48/48 (100.0%) 7 41
p 0.0098* 0.2193* 0.2858**
° IQR = interquartile range
* Mann -Whitney test
** Fisher’s exact test
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non-significant, higher degree of positive results (90% vs.
77%; p = 0.3110), and the median value of positive cells
was significantly higher (p = 0.0098) (Table 1). Children
with neurological symptoms had median values (31
positive cells/2 × 105 PBL) higher than symptomatic
babies with only abnormal biological parameters (2 posi-
tive cells/2 × 105 PBL; p = 0.0218).
All 67 plasma samples suitable for qPCR were posi-
tive. The order of magnitude of the viral load was 103
copies/ml in 52% of cases (35/67), of whom 80% were
asymptomatic. However, there were no significant differ-
ences between the median number of DNA copies/ml in
relation to the presence or absence of symptoms (p =
0.22, Table 1) or to the involvement of CNS in sympto-
matic babies (37,000 vs 7,300 copies/ml; p = 0.0878). As
shown in Figure 1, greater variability was detected with
the antigenemia test among symptomatic children than
in asymptomatic ones, but not with qPCR.
Sixty neonates were strong positives in DBS test
whereas the remaining 10 (14%) were weak positives.
The DBS test results as with qPCR were not related to
the presence or absence of symptoms at birth (p > 0.05;
Table 1) nor to the involvement of CNS (p > 0.05). The
median number of positive cells in the antigenemia test
and copies/ml were significantly higher in children with
strong positivity in the DBS test than in those with
weakly positive findings (Table 2).
Conclusions
In this study, two quantitative methods (the pp65 anti-
genemia test and qPCR) were compared with semi-
quantitative DBS test to assess the clinical relevance of
hCMV load determination in infected babies both symp-
tomatic and asymptomatic at birth.
In this and a previous study [8], the sensitivity of the
antigenemia test to identify an infection was 81% (CI95%:
69.3 to 89.1) and 84%, respectively, which was higher
than the 42% reported by Revello et al. [3]. This differ-
ence might be because of the smaller proportion of
Figure 1 Number of positive cells/2 × 105 (pp65) and log10 of the number of copies/ml (qPCR). The first and third quartiles are the limits
of the box, the inner line is the median, and the “whiskers” represent the smallest and largest values. Dots portray single observations.
Table 2 pp65 antigenemia and qPCR findings in children
with either a weakly or strongly positive DBS-test
Positive DBS test
pp65




weak strong weak strong





8 (100%) 59 (100%)








* Mann -Whitney test
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symptomatic neonates in the latter study. However all
these studies showed significantly higher median counts
of pp65 positive PBLs in symptomatic cases. The signifi-
cant difference in terms of pp65 positive PMN cells, but
not as plasma CMV DNA copies/ml, in relation to the
clinical situation at birth might be related to the type of
sample. Revello [3] and Lanari [5] detected significant
differences of viral load. testing fixed amounts of PBLs
Viral DNA was detected by PCR in the acellular blood
fraction of all the infants, as observed in other studies
[12,13], confirming the higher sensitivity of molecular
tests compared with immunological ones.
The quantitative PCR detected a median number of
copies/ml of the same order of magnitude (103) as that
reported by Halwachs-Baumann et al. [14] even if they
tested serum and not plasma. Bradford et al. detected
levels that were about one logarithm lower in children
with symptomatic infections involving the central ner-
vous system [15]. These viral load values could affect
the DBS test findings; in an external quality assessment
study, about half the laboratories were unable to detect
DNA from blood with a viral load of 103 copies/ml [16].
Of note, we noticed that there was a loss of titer of
about one log between fresh and dried blood samples.
As described in a review by Barbi et al. [11], the DBS
test must be repeated on a new series of three samples
to confirm a single positivity in about 10% of cases, sug-
gesting that this is indicative of a low viral load in the
blood. This was confirmed by the present study, where
a lower median level of both pp65-positive cells and
DNA copies was detected in weakly positive DBS sam-
ples, corresponding to 14% of all those tested. There-
fore, some of these cases were probably at the limit of
sensitivity and may be missed with DBS testing, particu-
larly if the method employed (sample size, elution,
extraction, amplification) and the algorithm for defining
positivity are less than optimal. Hence, it is necessary to
correctly perform this test and properly interpret the
test results.
A comparison of the semi-quantitative measures
obtained in DBS test with the quantitative results of
real-time PCR on the same samples is ongoing.
Finally, upon completion of clinical and audiological
follow-up, the prognostic value of quantitative and
semi-quantitative results could be assessed.
Acknowledgements
This study was supported in part by funding from Ministero della Salute
within the “Programma di ricerca sanitaria finalizzata - anno 2006” in the
framework of the project “Prevenzione, diagnosi, prognosi e terapia delle
infezioni virali nella gestante, nel feto e nel neonato”.
Author details
1Dipartimento di Sanità Pubblica - Microbiologia - Virologia, Università degli
Studi di Milano, Milan, Italy. 2Laboratorio di Riferimento Regionale per lo
Screening Neonatale, AO ICP, Milan, Italy. 3Istituto di Pediatria e
Neonatologia, Fondazione IRCCS “Ospedale Maggiore Policlinico, Mangiagalli
e Regina Elena”, Università degli Studi di Milano, Milan, Italy. 4Istituto di
Statistica Medica e Biometria “GA Maccacaro”, Università degli Studi di
Milano, Milan, Italy.
Authors’ contributions
SB, AM, VP, PD, MB participated in the conception and design of study,
performed the assays and contributed to the preparation of the manuscript.
CC, FM, LP provided clinical data and contributed to draft the manuscript.
AB and CR performed the statistical analysis of the results and provided
critical comments to improve the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 June 2009
Accepted: 11 February 2010 Published: 11 February 2010
References
1. Dollard SC, Grosse SD, Ross DS: New estimates of the prevalence of
neurological and sensory sequelae associated with congenital
cytomegalovirus infection. Red Med Virol 2007, 17(5):355-363.
2. Fowler KB, Mc Collister FP, Dahle AJ, Boppana SB, Britt WJ, Pass RF:
Progressive and fluctuating sensorineural hearing loss in children with
asymptomatic congenital Cytomegalovirus infection. J Pediatr 1997,
130:624-630.
3. Revello MG, Zavattoni M, Baldanti F, Sarasini A, Paolucci S, Gerna G:
Diagnostic and prognostic value of human cytomegalovirus load and
IgM antibody in blood of congenitally infected newborns. J Clin Virol
1999, 14:57-66.
4. Boppana SB, Fowler KB, Pass RF, Rivera LB, Bradford RD, Lakeman FD,
Britt WJ: Congenital cytomegalovirus infection: association between virus
burden in infancy and hearing loss. J Pediatr 2005, 146:817-823.
5. Lanari M, Lazzarotto T, Venturi V, Papa I, Gabrielli L, Guerra B, Landini MP,
Faldella G: Neonatal cytomegalovirus blood load and risk of sequelae in
symptomatic and asymptomatic congenitally infected newborns.
Pediatrics 2006, 117:76-83.
6. Walter S, Atkinson C, Sharland M, Rice P, Raglan E, Emery VC, Griffiths PD:
Congenital cytomegalovirus: association between dried blood spot viral
load and hearing loss. Arch Dis Child Fetal Neonatal 2008, 93:F280-F285.
7. Dobbins JG, Stewart JA, Demmler JG: Surveillance of congenital
cytomegalovirus disease, 1990-1991. CDC surveillance summaries: MMWR
1992, 41(SS-2):35-44.
8. Barbi M, Binda S, Primache V, Novelli C: Cytomegalovirus in peripheral
blood leukocytes of infants with congenital or postnatal infection.
Pediatr Infect Dis J 1996, 15:898-903.
9. Binda S, Caroppo S, Didò P, Primache V, Veronesi L, Calvario A, Piana A,
Barbi M: Modification of CMV DNA detection from dried blood spots for
diagnosing congenital CMV infection. J Clin Virol 2004, 30:276-279.
10. Wakefield AJ, Fox JD, Sawyerr AM, Taylor JE, Sweenie CH, Smith M,
Emery VC, Hudson M, Tedder RS, Pounder RE: Detection of herpesvirus
DNA in the large intestine of patients with ulcerative colitis and Crohn’s
disease using the nested polymerase chain reaction. J Med Virol 1992,
38:183-190.
11. Barbi M, Binda S, Caroppo S: Diagnosis of congenital CMV infection via
dried blood spots. Rev Med Virol 2006, 16:385-392.
12. Brytting M, Xu W, Wahren B, Sundqvist V: Cytomegalovirus DNA detection
in sera from patients with active cytomegalovirus infections. J Clin
Microbiol 1992, 30:1937-1941.
13. Barbi M, Binda S, Minolfi V, Novelli C, Primache V, Tagger A: HCMV
infection diagnosis by detection of viral DNA by PCR in serum or
plasma. Presented at the European Group for Rapid Diagnosis (EGRVD)
Meeting. Stockholm 1994.
14. Halwachs-Baumann G, Genser B, Pailer S, Engele H, Rosegger H, Schalk A,
Kessler HH, Truschnig-Wilders M: Human cytomegalovirus load in various
body fluids of congenitally infected newborns. J Clin Virol 2002, 25:
S81-S87.
15. Bradford RD, Cloud G, Lakeman A, Boppana SB, Kimberlin DW, Jacobs R,
Demmler G, Sanchez P, Britt W, Soong S, Whitley RJ, the National Institute
Binda et al. BMC Infectious Diseases 2010, 10:24
http://www.biomedcentral.com/1471-2334/10/24
Page 4 of 5
of Allergy and Infectious Diseases Collaborative Antiviral Study Group:
Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction
is associated with hearing loss in newborns with symptomatic
congenital CMV infection involving the central nervous system. J Infect
Dis 2005, 191:227-233.
16. Barbi M, MacKay WG, Binda S, van Loon A: External quality assessment of
cytomegalovirus DNA detection on dried blood spots. BMC Microbiology
2008, 8:2.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2334/10/24/prepub
doi:10.1186/1471-2334-10-24
Cite this article as: Binda et al.: Pp65 antigenemia, plasma real-time PCR
and DBS test in symptomatic and asymptomatic cytomegalovirus
congenitally infected newborns. BMC Infectious Diseases 2010 10:24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Binda et al. BMC Infectious Diseases 2010, 10:24
http://www.biomedcentral.com/1471-2334/10/24
Page 5 of 5
